| 3.675 -0.045 (-1.21%) | 07-31 10:51 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.81  |
1-year : | 5.22 |
| Resists | First : | 4.12 |
Second : | 4.47 |
| Pivot price | 3.86 |
|||
| Supports | First : | 3.55 | Second : | 2.96 |
| MAs | MA(5) : | 3.69 |
MA(20) : | 3.95 |
| MA(100) : | 4.13 |
MA(250) : | 4.72 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 13.6 |
D(3) : | 14.3 |
| RSI | RSI(14): 37.4 |
|||
| 52-week | High : | 7.55 | Low : | 2.93 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AQST ] has closed above bottom band by 16.1%. Bollinger Bands are 9.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.74 - 3.76 | 3.76 - 3.78 |
| Low: | 3.56 - 3.58 | 3.58 - 3.59 |
| Close: | 3.69 - 3.72 | 3.72 - 3.75 |
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
Fri, 31 Jul 2026
AQST|Aquestive Therapeutics Inc|Price:3.725|Chg%:+0.125 - TradingKey
Fri, 31 Jul 2026
Aquestive Therapeutics Inc (AQST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fri, 17 Jul 2026
Insider Sell: Aquestive Therapeutics Inc (AQST) President and CE - GuruFocus
Wed, 24 Jun 2026
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 125 (M) |
| Shares Float | 115 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 58.7 (%) |
| Shares Short | 16,670 (K) |
| Shares Short P.Month | 14,800 (K) |
| EPS | -0.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.28 |
| Profit Margin | -137.1 % |
| Operating Margin | -29.2 % |
| Return on Assets (ttm) | -28.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 65.6 % |
| Gross Profit (p.s.) | 0.25 |
| Sales Per Share | 0.4 |
| EBITDA (p.s.) | -0.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -5.97 |
| PEG Ratio | 0 |
| Price to Book value | -13.49 |
| Price to Sales | 9.08 |
| Price to Cash Flow | -10.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|